Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer - Full Text View - ClinicalTrials.gov
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
This study is currently recruiting participants.
Verified April 2012 by Stanford University
First Received on December 13, 2011.
Last Updated on April 18, 2012
History of Changes
Sponsor: | Stanford University |
---|---|
Information provided by (Responsible Party): | Stanford University |
ClinicalTrials.gov Identifier: | NCT01494012 |
This
phase I trial studies the side effects and the best dose of stereotactic
body radiation therapy (SBRT) in treating patients with metastatic or
recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.